« Return to News | Drug Sponsors

Pfizer to invest $200 million in Irish facility

Tuesday, September 20, 2011 01:33 PM

Pfizer has announced that it is to invest $200 million at its Grange Castle biotechnology manufacturing facility in Clondalkin, Co Dublin, according to PharmaTimes.

The investment will enable the drugs giant to introduce two new processing suites to the site and expand current production and product testing capabilities. Grange Castle is already one of the largest biotech manufacturing facilities in the world and currently produces two blockbusters - the pneumococcal disease vaccine Prevnar and the arthritis and psoriasis therapy Enbrel. The site currently employs 1,100 full-time staff.

Pfizer's chief financial officer, Frank D’Amelio, noted that with pharmaceutical and chemical products accounting for over 50% of Irish exports "and a long history in pharmaceutical excellence, Ireland is a prime location for this major investment.” He added that the Grange Castle project is "a strategic initiative that will allow us to further align and strengthen our manufacturing and supply network.”

The news was announced by Irish Taoiseach (prime minister) Enda Kenny, who noted that Pfizer has made "a tremendous contribution to Ireland’s life sciences industry since it first established here in 1969 and this investment is a further demonstration of the company’s continuous commitment" to the country.

Pfizer has some 4,300 staff in Ireland across eight locations based in Cork, Dublin, Kildare and Limerick. Total investment by the company in the country exceeds $7 billion.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.